February due to contamination issues.The closure of the Sturgis facility, the largest in the U.S. and source of leading brands like Similac, exacerbated the industry-wide baby formula shortage.
For several months, parents and caregivers have been scrambling as shelves increasingly become more barren. Meanwhile, retailers were forced to put purchasing limits on the product to try and curtail stockpiling.ABBOTT TO REOPEN MICHIGAN FACILITY ON JUNE 4, PRIORITIZE PRODUCTION OF SPECIALTY FORMULAThe company, which has notified the U.S.
Food and Drug Administration, said the incident will likely delay the production and distribution of the infant formula for a few weeks."Abbott has ample existing supply of EleCare and most of its specialty and metabolic formulas to meet needs for these products until new product is available," according a statement."Once the plant is re-sanitized and production resumes, we will again begin EleCare production, followed by specialty and metabolic formulas.
In parallel, we will work to restart Similac production at the plant as soon as possible," the statement continued.U.S. Food and Drug Administration Commissioner Dr.